About Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial (IDH3A) is a protein
from Homo sapiens identified by UniProt accession
P50213, 366 residues long.
MolForge cross-references it against 0 known binders and
283 disease associations.
Target properties
| Protein name | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial |
| UniProt accession | P50213 |
| Gene | IDH3A |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (283)
Diseases linked to this target (Open Targets).
- retinitis pigmentosa 90 · score 0.78
- retinitis pigmentosa · score 0.46
- neurodegenerative disease · score 0.44
- colorectal carcinoma · score 0.18
- Cone rod dystrophy · score 0.10
- neoplasm · score 0.10
- X-linked retinal dysplasia · score 0.09
- age-related macular degeneration · score 0.09
- Best vitelliform macular dystrophy · score 0.08
- Familial exudative vitreoretinopathy · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50213-F1 | alphafold | PREDICTED | 90.66 | — |
Amino-acid sequence (366 residues)
MAGPAWISKV SRLLGAFHNP KQVTRGFTGG VQTVTLIPGD GIGPEISAAV MKIFDAAKAP IQWEERNVTA IQGPGGKWMI PSEAKESMDK NKMGLKGPLK TPIAAGHPSM NLLLRKTFDL YANVRPCVSI EGYKTPYTDV NIVTIRENTE GEYSGIEHVI VDGVVQSIKL ITEGASKRIA EFAFEYARNN HRSNVTAVHK ANIMRMSDGL FLQKCREVAE SCKDIKFNEM YLDTVCLNMV QDPSQFDVLV MPNLYGDILS DLCAGLIGGL GVTPSGNIGA NGVAIFESVH GTAPDIAGKD MANPTALLLS AVMMLRHMGL FDHAARIEAA CFATIKDGKS LTKDLGGNAK CSDFTEEICR RVKDLD
Explore Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets